Cover Image
Market Research Report

North America Antihypertensive Drugs Market 2019-2028

Published by Inkwood Research Product code 943441
Published Content info 129 Pages
Delivery time: 2-3 business days
Price
Back to Top
North America Antihypertensive Drugs Market 2019-2028
Published: June 21, 2020 Content info: 129 Pages
Description

KEY FINDINGS

The North America antihypertensive drugs market is predicted to record a CAGR of 3.28% during the forecast period, 2019 to 2028. The growth rate is attributed to factors such as the surge in the predominance of hypertension and persistent kidney disorders. Moreover, prominent players like Johnson & Johnson and Merck & Co., Inc. promote market growth in this region.

MARKET INSIGHTS

The evaluation of the North America antihypertensive drugs market growth involves the market analysis of Canada and the United States. Canada's clinical practice regulations for the management of hypertension are in accordance with the Hypertension Canada Guidelines. They are developed by an expert volunteer network and are meticulously reviewed and regularly updated to keep healthcare professionals notified about hypertension management. According to statistics, the expenses designated to hypertension in Canada were estimated at more than $13 billion, and are expected to considerably increase over the years. Moreover, Canada's increased rates of awareness, medication, and management are instituted due to the combined efforts established by health care professionals and organizations. This is done in view of decreasing the weight of hypertension and efficient knowledge interpretation regarding hypertension and its subsequent risks. Therefore, these factors significantly contribute to driving the antihypertensive drugs market in Canada.

COMPETITIVE INSIGHTS

Merck & Co Inc, Johnson & Johnson, Lupin Limited, Novartis AG, Hill-Rom Holdings Inc, Sun Pharmaceutical Industries Ltd (Ranbaxy Laboratories), are some of the distinguished companies operating in the market.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 32271

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF HYPERTENSION ACROSS THE GLOBE
    • 3.2.2. SURGE IN DISPOSABLE INCOME AND HEALTHCARE SPENDING
    • 3.2.3. RISING AGING POPULATION
  • 3.3. KEY RESTRAINTS
    • 3.3.1. PATENT EXPIRATIONS
    • 3.3.2. DELAY IN PRODUCT LAUNCHES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. REGULATORY FRAMEWORK
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY DRUG CLASS

  • 5.1. CALCIUM CHANNEL BLOCKERS
  • 5.2. ACE INHIBITORS
  • 5.3. BETA-ADRENERGIC BLOCKERS
  • 5.4. DIURETICS
  • 5.5. VASODILATORS
  • 5.6. OTHER DRUG CLASS

6. MARKET BY END-USER

  • 6.1. HOSPITAL PHARMACY
  • 6.2. RETAIL PHARMACY
  • 6.3. E-COMMERCE WEBSITES & ONLINE DRUG STORES

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA

8. COMPANY PROFILES

  • 8.1. ALLERGAN PLC
  • 8.2. ASPIRE BARIATRICS INC
  • 8.3. ASTRAZENECA PLC
  • 8.4. BIO-RAD LABORATORIES INC
  • 8.5. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 8.6. DAIICHI SANKYO COMPANY LIMITED
  • 8.7. HILL-ROM HOLDINGS INC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. LUPIN LIMITED
  • 8.10. MEDTRONIC PLC
  • 8.11. MERCK & CO INC
  • 8.12. NOVARTIS AG
  • 8.13. PFIZER INC
  • 8.14. SANOFI
  • 8.15. SUN PHARMACEUTICAL INDUSTRIES LTD (RANBAXY LABORATORIES)

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ANTIHYPERTENSIVE DRUGS
  • TABLE 2: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 4: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, IN 2019
  • FIGURE 6: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY CALCIUM CHANNEL BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 7: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY ACE INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 8: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY BETA-ADRENERGIC BLOCKERS, 2019-2028 (IN $ MILLION)
  • FIGURE 9: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DIURETICS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY VASODILATORS, 2019-2028 (IN $ MILLION)
  • FIGURE 11: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY OTHER DRUG CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, IN 2019
  • FIGURE 13: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY HOSPITAL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 14: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY RETAIL PHARMACY, 2019-2028 (IN $ MILLION)
  • FIGURE 15: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY E-COMMERCE WEBSITES & ONLINE DRUG STORES, 2019-2028 (IN $ MILLION)
  • FIGURE 16: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 17: THE UNITED STATES ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 18: CANADA ANTIHYPERTENSIVE DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top